CA2053187A1 - Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper» - Google Patents

Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper»

Info

Publication number
CA2053187A1
CA2053187A1 CA 2053187 CA2053187A CA2053187A1 CA 2053187 A1 CA2053187 A1 CA 2053187A1 CA 2053187 CA2053187 CA 2053187 CA 2053187 A CA2053187 A CA 2053187A CA 2053187 A1 CA2053187 A1 CA 2053187A1
Authority
CA
Canada
Prior art keywords
expression
recombinant
adenovirus
proteins
enhancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2053187
Other languages
English (en)
Inventor
Bernard Massie
Yves Langelier
Nathalie Lamarche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council Of Canada
Bernard Massie
Yves Langelier
Nathalie Lamarche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council Of Canada, Bernard Massie, Yves Langelier, Nathalie Lamarche filed Critical National Research Council Of Canada
Priority to CA 2053187 priority Critical patent/CA2053187A1/fr
Publication of CA2053187A1 publication Critical patent/CA2053187A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA 2053187 1991-10-10 1991-10-10 Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper» Abandoned CA2053187A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2053187 CA2053187A1 (fr) 1991-10-10 1991-10-10 Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper»

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2053187 CA2053187A1 (fr) 1991-10-10 1991-10-10 Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper»

Publications (1)

Publication Number Publication Date
CA2053187A1 true CA2053187A1 (fr) 1993-04-11

Family

ID=4148542

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2053187 Abandoned CA2053187A1 (fr) 1991-10-10 1991-10-10 Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper»

Country Status (1)

Country Link
CA (1) CA2053187A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994106A (en) * 1994-06-10 1999-11-30 Genvec, Inc. Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus
US6238893B1 (en) 1995-06-15 2001-05-29 Introgene B.V. Method for intracellular DNA amplification
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7846450B2 (en) 1996-07-11 2010-12-07 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Melanoma associated peptide analogues and vaccines against melanoma
US7989426B2 (en) 2002-02-15 2011-08-02 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease by expression of PEDF

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482616B1 (en) 1994-06-10 2002-11-19 Genvec, Inc. RCA-free adenoviral vector system and propagation method
US7195896B2 (en) 1994-06-10 2007-03-27 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5994106A (en) * 1994-06-10 1999-11-30 Genvec, Inc. Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus
US7105346B2 (en) 1995-06-15 2006-09-12 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US8236293B2 (en) 1995-06-15 2012-08-07 Crucell Holland B.V. Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer
US6306652B1 (en) 1995-06-15 2001-10-23 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6602706B1 (en) 1995-06-15 2003-08-05 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6395519B1 (en) 1995-06-15 2002-05-28 Introgene B.V. Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer
US6692966B2 (en) 1995-06-15 2004-02-17 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6238893B1 (en) 1995-06-15 2001-05-29 Introgene B.V. Method for intracellular DNA amplification
US7052881B2 (en) 1995-06-15 2006-05-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US8075900B2 (en) 1996-07-11 2011-12-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Melanoma associated peptide analogues and vaccines against melanoma
US7846450B2 (en) 1996-07-11 2010-12-07 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Melanoma associated peptide analogues and vaccines against melanoma
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7037716B2 (en) 1998-04-24 2006-05-02 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6878549B1 (en) 1998-04-24 2005-04-12 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7029848B2 (en) 1998-06-12 2006-04-18 Galapagos Genomics N.V. High throughput screening of gene function using libraries for functional genomics applications
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US7989426B2 (en) 2002-02-15 2011-08-02 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease by expression of PEDF

Similar Documents

Publication Publication Date Title
US5518913A (en) High level recombinant protein production using conditional helper-free adenovirus vector
CA2074502C (fr) Vaccins
Fender et al. Adenovirus dodecahedron, a new vector for human gene transfer
US5770442A (en) Chimeric adenoviral fiber protein and methods of using same
Bett et al. Packaging capacity and stability of human adenovirus type 5 vectors
EP1056881B1 (fr) Un system simplifie pour la generation d'adenovirus recombinants
Schiedner et al. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production
EP0935648B1 (fr) Vecteurs d'adenovirus perfectionnes
CA2238295C (fr) Systemes de vecteurs adenoviraux et de lignees cellulaires complementaires
EP0704534B1 (fr) Vecteur ADN viral récombinant pour la transfection de cellules animales
US5700470A (en) Recombinant adenovirus with removed EZA gene and method of preparation
US7195896B2 (en) Complementary adenoviral vector systems and cell lines
EP0705344B1 (fr) Vecteurs a base d'adenovirus destines a la therapie genique
US7067309B2 (en) Defective adenoviruses and corresponding complementation lines
US6140087A (en) Adenovirus vectors for gene therapy
JP4733795B2 (ja) ヒツジアデノウイルスベクターを用いた遺伝子治療
NO321309B1 (no) Defektive, rekombinante adenovirus, cellelinje, samt et farmasoytisk preparat.
CZ230697A3 (en) Cells for producing recombinant adenoviruses
Massie et al. Improved adenovirus vector provides herpes simplex virus ribonucleotide reductase R1 and R2 subunits very efficiently
Loser et al. Advances in the development of non-human viral DNA-vectors for gene delivery
CA2053187A1 (fr) Production efficace d'une proteine recombinante a l'aide d'un vecteur adenoviral conditionnel sans «helper»
JP2003508057A (ja) 改変アデノウイルスファイバーおよび用途
CA2318737A1 (fr) Procedes de fabrication de vecteurs pseudo-adenoviraux
WO1999053085A2 (fr) Regulation selective de la production d'adenovirus
Gall et al. Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead